Protein
Schematic diagram of the DDR1 protein and localization of the DDR1 Tyrosine phosphorylated sites at intracellular domain.
Description
DDR1 belongs to the DDRs subfamily of tyrosine kinase receptors. This subfamily is composed of only two members, DDR1 and DDR2, and it is distinguished by an extracellular domain that is homologous to the carbohydrate-binding lectin discoidin-I in Dictyostelium discoideum. The Discoidin domain is essential for the ability of DDRs to bind ligands. Todate, collagen is the only unique DDR1 ligand that has been identified. Five isoforms of DDR1 that are generated by alternative splicing have been described. The longest DDR1 transcript codes for the full-length receptor (DDR1c isoform) and is composed of 919 amino acids. DDR1a and DDR1b isoforms lack 37 amino acids in the juxtamembrane domain or 6 amino acids in the kinase domain. DDR1d and DDR1e isoforms are C-terminally truncated receptors. DDR1d lacks exons 11 and 12 causing a frame-shift mutation that generates a stop codon and premature termination of transcription. Finally, DDR1e lacks exons 11 and 12 as well as the first half of exon 10 (Alves et al., 1995) .
Expression
DDR1 is ubiquitously expressed in a variety of epithelial tissues (Alves et al., 1995; Curat and Vogel, 2002; Ferri et al., 2004; Hou et al., 2001; Mohan et al., 2001; Sakamoto et al., 2001; Tanaka et al., 1998) . DDR1 is also expressed in endothelial blood capillary cells and oligodendrocytes in the human brain (FrancoPons et al., 2009; Roig et al., 2010) . DDR1 is significantly overexpressed in several human cancers (Barker et al., 1995; Colas et al., 2011; Ford et al., 2007; Hajdu et al., 2010; Heinzelmann-Schwarz et al., 2004; Laval et al., 1994; Nemoto et al., 1997; Park et al., 2007; Tun et al., 2011; Weiner et al., 1996; Weiner et al., 2000; Yamanaka et al., 2006; Yoshida et al., 2007) and carcinoma cell lines (Alves et al., 1995; Gu et al., 2011; Park et al., 2007; Sakuma et al., 1996) .
Localisation
Transmembrane.
Function
Receptor tyrosine kinases are key components of several signal transduction pathways. These kinases control multiple cellular processes, including motility, proliferation, differentiation, metabolism and survival. DDR1 is actively involved in tumorigenesis and promotes the proliferation of neoplasic cells. The interaction of DDR1 and Notch1 displays a prosurvival effect (Kim et al., 2011) . DDR1 participates in the collective migration of cancer cells by coordinating the cell polarity regulators Par3 and Par6 (Hidalgo-Carcedo et al., 2011).
Homology
-P. troglodytes, discoidin domain receptor tyrosine kinase 1, DDR1 -C. lupus, discoidin domain receptor tyrosine kinase 1, DDR1 -M. musculus, discoidin domain receptor family member 1, Ddr1 -R. norvegicus, discoidin domain receptor tyrosine kinase 1 -D. rerio, discoidin domain receptor family member 1
Mutations
Note Few somatic mutations have been described. Four mutations (G1486T, A496S, CC2469/2470TT, R824W) have been identified in a cohort of 26 primary lung neoplasms (Davies et al., 2005) . One somatic mutation (A803V) was found in 4 acute myeloid leukaemia patients (Tomasson et al., 2008) .
Implicated in

Breast cancer
Note DDR1 overexpression was observed in human primary breast tumours samples compared to that in normal breast tissues (Barker et al., 1995) . In addition, invasive ductal and lobular carcinomas showed differential expression of DDR1. DDR1 was downregulated in lobular carcinomas (Turashvili et al., 2007a; Turashvili et al., 2007b) .
Osteosarcoma
Note
The DDR1 promoter presents a potential p53 bindingsite. A previous study has shown that p53 expression upregulated the mRNA expression levels of DDR1 in human osteosarcoma cells (Sakuma et al., 1996) .
Oesophageal cancer
Note
The overexpression of DDR1 was reported in 12 carcinomatous oesophageal tissues compared to that in normal tissues. Furthermore, a positive correlation was identified between DDR1 mRNA expression and the proliferative activity of the tumoural cells (Nemoto et al., 1997).
Ovarian cancer
Note DDR1 was highly expressed in 158 histological subtypes of primary epithelial ovarian cancers (EOC) compared to that in normal ovarian surface epithelium samples (Heinzelmann-Schwarz et al., 2004) .
Endometrial cancer
Note DDR1 has been implicated as a potential molecular marker of endometrial cancer (Colas et al., 2011; Domenyuk et al., 2007) . A gene expression screening of 52 carcinomas samples showed differential expression of several genes, including the DDR1 gene. These data were also demonstrated in 50 tumoural and non-tumoural uterine aspirates (Colas et al., 2011) .
Brain tumours
Note DDR1 was originally isolated in malignant childhood brain tumours, which overexpressed DDR1 (Weiner et al., 1996) . Replicable findings were found in metastatic brain neoplasms and glioma cells (Yamanaka et al., 2006; Weiner et al., 2000) . In glioma cells, DDR1 was involved in cell proliferation and invasion via cell interactions with the extracellular matrix (Ram et al., 2005; Yamanaka et al., 2006) . Moreover, a study on DDR1a and DDR1b isoforms overexpression in glioma cells has identified distinct roles for each DDR1 isoforms in the cell attachment process, which is mediated by collagen I (Ram et al., 2005) . The analysis of the expression profile in mice that had PDGFinduced glioma showed overexpression of DDR1 (Johansson et al., 2005) .
Primary central nervous system lymphoma (PCNSL)
Note A PCNSL pathway analysis revealed upregulation of DDR1 expression in the extracellular matrix and the adhesion-related pathways (Tun et al., 2011) .
Pituitary adenoma
Note
In different subtypes of pituitary adenoma, DDR1 expression was related to the hormonal background. DDR1 was more highly expressed in macroadenomas, compared to microadenomas, and in PRL-and GHproducing adenomas (Yoshida et al., 2007) .
Lung cancer
Note DDR1 was upregulated in tumour lung tissue compared to that in normal tissue and was an independent favourable predictor for prognosis (Ford et al., 2007) . Similarly, DDR1 was highly phosphorylated in nonsmall cell lung cancer (NSCLC) (Rikova et al., 2007) . One study described the presence of DDR1 somatic mutations in lung cancer (Davies et al., 2005) . However, no mutations were detected in another lung cancer study (Ford et al., 2007) .
Liver cancer
Note DDR1a and DDR1b isoforms were overexpressed in hepatocellular carcinoma cell lines HLE and Huh-7. DDR1 isoform overexpression enhanced the migration and invasion of the hepatocellular carcinoma cell lines in association with the matrix metalloproteinases MMP2 and MMP9 (Park et al., 2007) . The downregulation of miR-199a-5p, which is a direct target of DDR1, deregulated DDR1 functionality and increased cell invasion in human hepatocellular carcinoma (HCC) (Shen et al., 2010) . Finally, a profiling study on receptor tyrosine kinase phosphorylation in cholangiocarcinoma patients showed high levels of phosphorylation of DDR1 and other tyrosine kinases in tumour tissues in comparison to para-tumour tissues (Gu et al., 2011) .
Mesenchymal neoplasm
Note
Solitary fibrous tumour (SFT) expression profiling of 23 samples showed an over-expression of several receptor tyrosine kinase genes, including DDR1. However, no mutations were identified using cDNA sequencing (Hajdu et al., 2010) .
